Rectified Essential Oil of Pogostemon cablin (Lamiaceae) with high content in alpha and delta guaiene obtained from leaves by distillation.

Endpoint summary

Description of key information

According to clinical study (human repeat patch test) test item was considered as non-irritating and non-sensitising.

Key value for chemical safety assessment

Skin sensitisation

Link to relevant study records

Reference

Reference 1

Endpoint:

skin sensitisation: in vivo (non-LLNA)

Remarks:

Human Repeat Insult Patch Test

Type of information:

experimental study

Adequacy of study:

key study

Study period:

9 January to 17 February 2012

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

test procedure in accordance with generally accepted scientific standards and described in sufficient detail

Reason / purpose for cross-reference:

reference to same study

Qualifier:

no guideline followed

Principles of method if other than guideline:

MARZULLI-MAIBACH METHOD: The Marzulli-Maibach test is a reference test to study the sensitizing potential of a product. The investigational product was applied under maximized conditions (occlusion) during 3 weeks (Induction phase). After a two-week resting period, the investigational product was re-applied on the same site (Challenge phase). If the investigational product was allergenic, it induced a cutaneous reaction during the challenge phase.

GLP compliance:

no

Remarks:

Good clinical practice

Type of study:

other: Study with volunteers

Justification for non-LLNA method:

Available study on volunteers

Specific details on test material used for the study:

SOURCE OF TEST MATERIAL
- Source and lot/batch No.of test material: Robertet / 1928083
- Appearance: Liquid
- Date of receipt: 07 December 2011

STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: Between 15 °C and 25 °C

Species:

other: Human

Strain:

other: non relevant

Sex:

male/female

Details on test animals and environmental conditions:

- Number of subjects recruited: 115
- Number of subjects exposed: 102
- Sex: 26 men and 76 women
- Age: Average age: 34.8 ± 12.9 years old (extreme values: 19 - 63 years old).
Others:
- Non-Included: 7 (did not fulfill the inclusion criteria at Day 1)
- Study premature withdrawals: 6 (Subjects no.19 and 53: Subjects' decision to withdrawal from the study at Day 3 because of strong smell of the products; Subjects no. 11 and 93: Subjects' decision to withdrawal from the study at Day 5 because of strong smell of the products; Subject no. 28: Lost to follow-up at Day 36; Subject no. 60: Lost to follow-up at Day 15)
Ethical approval: confirmed and informed consent free of coercion received

The subjects were included according to the following criteria:
Inclusion criteria:
The voluntary subjects satisfied the following criteria:
Female or male,
Aged from 18 to 70 years old,
Not showing tattoo, scars, pigmented areas, important pilosity and dermatological lesions on the back and not receiving any anti-inflammatory or anti-allergic medication,
Subjects with Social Security (health insurance) coverage (according to the requirements of the MACEDONIAN REPUBLIC),
Able and willing to give a written informed consent.
 
Non-inclusion criteria:
The voluntary subjects did not satisfy the following criteria:
Who had applied a care product on the sites of application during the 24 hours before the beginning of the study,
Who had not washed the sites of the application with water 2 hours before the beginning of the study,
Pregnant woman or in the process of breast feeding,
Who had taken part to a patch test in the 15 days before the beginning of the study,
Who had tattoos on the back,
Who had scars on the back,
Who showed pigmented areas on the back,
Who had a very important pilosity on the back,
Who showed dermatological lesions on the back,
Presenting a medical history of medical or psychiatric illness, or of allergy to cosmetic products, or of major surgery, likely to be a health hazard for them according to the investigator,
Who suffered from any acute or chronic illnesses,
Who were under drugs or under a period of pharmacological efficacy,
Who presented confusions due to the excessive alcohol absorption or toxic substances,
Who presented dermatological inflammations,
Who were under a medical treatment, including an anti-allergic or anti-inflammatory treatment,
Unwilling to give their written informed consent,
PERITESCO's or I.C.T.C' s employees,
Who could not be contacted in case of emergency by phone,
Who did not fulfill the above inclusion criteria.

Positive control results:

No positive control

Key result

Reading:

2nd reading

Hours after challenge:

48

Group:

test chemical

Dose level:

Patchouli Fraction Alpha Guaiene 8% undiluted

No. with + reactions:

0

Total no. in group:

102

Clinical observations:

No significant clinical manifestation of intolerance or allergy was observed by the investigator.

Remarks on result:

no indication of skin sensitisation

Reading:

other: Non performed

Group:

negative control

Remarks on result:

not measured/tested

Reading:

other: Non perfomed

Group:

positive control

Remarks on result:

not measured/tested

Table 7.10.4/1: Induction phase – results

Days	Investigational product	% of subjects - reaction	Semi-Occlusive control	% of subjects - reaction
Day 1	Normal examination	0	Normal examination	0
Day 3	No reaction	0	No reaction	0
Day 5/6*	No reaction	0	No reaction	0
Day 8	No reaction	0	No reaction	0
Day 10	No reaction	0	No reaction	0
Day 12/13*	No reaction	0	No reaction	0
Day 15	No reaction	0	No reaction	0
Day 17	No reaction	0	No reaction	0
Day 19/20*	No reaction	0	No reaction	0
Day 22	No reaction	0	No reaction	0
Day 24**	No reaction	0	No reaction	0

* Subjects no. 104, 105, 106, 107 and 108 began the study 2 days later, so they did not have any visit at Day 5, Day 12 and Day 19, but at Day 6, Day 13 and Day 20.

** Additional application day for subjects no. 3, 13, 67, 69, 89, 95, 97 and 103 as they did not have any application nor reading performed one day during the induction phase.

Table 7.10.4/2: Challenge phase – results

Days	Sites	Investigational product	% of subjects - reaction	Semi-Occlusive control	% of subjects - reaction
Day 34/36*	H	Normal examination	0	Normal examination	0
	C	Normal examination	0	Normal examination	0
Day 36/38*	H	No reaction	0	No reaction	0
	C	No reaction	0	No reaction	0
Day 37/39*	H	No reaction	0	No reaction	0
	C	No reaction	0	No reaction	0
Day 38/40*	H	No reaction	0	No reaction	0
	C	No reaction	0	No reaction	0

H: homolateral site;C: contralateral site

* Subjects no.104, 105, 106, 107 and 108 began the study2days later, therefore their challenge phase was performed on Day34,Day 36,Day37and Day38 instead of Day36, Day38,Day39 and Day 40.

Interpretation of results:

GHS criteria not met

Conclusions:

Under the conditions of the study, the investigational product PATCHOULI FRACTION (ALPHA GUAIENE) 290737 8% (3646 µg/cm2) EtOH/DEP(25/75) lot 1928083 tested undiluted, under semi occlusive patch, can be considered as non-sensitizing.

Executive summary:

A cutaneous tolerance and sensitizing potential study of the investigational product, PATCHOULI FRACTION (ALPHA GUAIENE) 290737 8% (3646µg/cm²) EtOH/DEP(25/75) lot 1928083 tested undiluted was conducted by patches application, according to the Marzulli-Maibach sensitization method. The data of 102 female and male subjects aged from 19 to 63 years old were analyzed during the study. The subjects were willing and able to give a written informed consent. The study was carried out at the clinical unit of Skopje in MACEDONIA. The study was blinded and randomized.

Duration:Induction phase: 3 weeks (3 times a week during 48 hours or 72 hours); Duration Resting phase: 14 days; Challenge phase: 1 week (once during 48 hours)

 

INDUCTION PHASE: During the Induction Phase, the investigational product was applied (160 µL) on a predetermined site under semi occlusive patch (back). A semi-occlusive patch receiving no product was applied in the same conditions and was considered as a non-treated control. Each time, the patches (treated and non-treated) remained applied during 48 or 72 hours before removal and replaced on the same site.

RESTING PHASE: During the 14-day Resting Phase, no product was applied on the sites used during the Induction phase or on the contralateral split-back which was used during the Challenge phase.

CHALLENGE PHASE: During the challenge phase (Day 34/36*), the investigational product was applied under semi occlusive patch on the induction sites and on the contralateral sites. A semi occlusive patch receiving no product was applied in the same conditions and was considered as a non-treated control. The patches (treated and non-treated) remained applied during 48 hours and removed afterwards.

 

A clinical examination was performed by the investigating dermatologist during the Induction Phase on Days 1, 3,5/6,8, 10,12/13,15, 17,19/20and22/24,and during the Challenge Phase on Days34/36, 36/38, 37/39and38/40.

 

During the induction phase, no sign was observed on the control site and the investigational product site. During the challenge phase, no sign was observed on the control site and on the investigational product site, neither on the homolateral side nor on the controlateral site. In this study, no adverse event or serious adverse event was observed by the investigating dermatologists. No significant clinical manifestation of intolerance or allergy was observed by the investigator. The investigational product presents an irritation index of: Z = 0.000; the investigational product is therefore considered as practically non-irritant.

 

Under the conditions of the study, the investigational product PATCHOULI FRACTION (ALPHA GUAIENE) 290737 8% (3646 µg/cm2) EtOH/DEP(25/75) lot 1928083 tested undiluted, under semi occlusive patch, can be considered as non-sensitizing.

Reference 2

Endpoint:

skin sensitisation: in vitro

Data waiving:

study scientifically not necessary / other information available

Justification for data waiving:

an in vitro skin sensitisation study does not need to be conducted because adequate data from an in vivo skin sensitisation study are available

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed (not sensitising)

Additional information:

Under the conditions of the study, the investigational product PATCHOULI FRACTION (ALPHA GUAIENE) tested undiluted, under semi occlusive patch, can be considered as non-sensitizing.

Respiratory sensitisation

Endpoint conclusion

Endpoint conclusion:

no study available

Justification for classification or non-classification

In a human repeat insult patch test, the test item was concluded to be non-irritating and non-sensitising.

Based on this result and due to the nature of the main constituents of the registered substance, the registered substance does not need to be classified as skin sensitiser.